Fairvalue-Calculator Fairvalue-Calculator
EN DE

TaiRx, Inc (6580) Fair Value & Analysis

Healthcare · TW · Market cap 1.6B TWD

Price13.80 TWD
Fair Value11.82 TWD
Upside-14.3%
Quality95/100
Evidence: Low Range 8.86 TWD – 14.77 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

TaiRx, Inc (6580) currently trades at 13.80 TWD, while our model-based Fair Value estimate is 11.82 TWD — implying the stock looks roughly 14.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is TaiRx, Inc (6580) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 11.82 TWD versus a price of 13.80 TWD — about −14% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6580?
Our 21-model fair value for TaiRx, Inc is 11.82 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 13.80 TWD.
What is the quality score of 6580?
TaiRx, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.